Attention Deficit Hyperactivity Disorder Treatment Market, by Drug Type (Stimulants, Non-stimulants ), by Age Group, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

The global attention deficit hyperactivity disorder (ADHD) treatment market comprises therapeutics used for the treatment of attention deficit hyperactivity disorder. There are various therapeutics such as stimulants, which include stimulant drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate and non-stimulant drugs such as Atomoxetine, Bupropion, Guanfacine, and Clonidine. There are three types of attention deficit hyperactivity disorder (ADHD) such as predominantly inattentive presentation, predominantly hyperactive-impulsive presentation, and combined presentation. Various causes of attention deficit hyperactivity disorder (ADHD) include brain injury, alcohol and tobacco use during pregnancy, premature delivery, and low birth weight. It is a chronic condition which affects millions of children and often continue until the adulthood. Children with attention deficit hyperactivity disorder often suffer and struggle with low self-esteem and poor performance in school. Attention deficit hyperactivity disorder are not curable but can deal with symptoms. Treatment of attention deficit hyperactivity disorder involves medications as well as behavioral intervention. ADHD mainly have symptoms of inattention. ADHD probably results from a combination of factors such as genetics, researchers are looking at possible environmental factors that might raise the risk of developing ADHD and are studying how brain injuries, nutrition, and social environments might play a role in ADHD.

Market Dynamics

Key players are focusing on technological advancements to strengthen their position in the global attention deficit hyperactivity disorder (ADHD) treatment market. For instance, in June 2020, Akili Interactive Labs, a digital medicine prescription company received the U.S. Food Drug and Administration clearance for EndeavorRxTM (AKL-T01), a prescription medicine treatment for children with attention deficit hyperactivity disorder (ADHD). EndeavorRxTM is used to treat and to improve attention in children suffering from ADHD.

Key features of the study:

• This report provides an in-depth analysis of the global attention deficit hyperactivity disorder treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global attention deficit hyperactivity disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amnel Pharmaceuticals LLC., Eli Lilly And Company, Johnson & Johnson Services, Inc., Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Purdue Pharma L.P. ,Cingulate, Adlon Therapeutics L.P., Tris Pharma, Inc.,Neuraxpharm, Supernus Pharmaceuticals,Inc., and Aytu Biopharma, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global attention deficit hyperactivity disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global attention deficit hyperactivity disorder treatment market

Detailed Segmentation:

• Global Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type:
  • Stimulants
    • Amphetamine
    • Methylphenidate
    • Dextroamphetamine
    • Dexmethylphenidate
    • Lisdexamfetamine Dimesylate
  • Non-stimulants
    • Atomoxetine
    • Bupropion
    • Guanfacine
    • Clonidine
• Global Attention Deficit Hyperactivity Disorder Treatment Market, By Age Group:
  • Pediatric and Adolescent
  • Adult
• Global Attention Deficit Hyperactivity Disorder Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Attention Deficit Hyperactivity Disorder Treatment Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Amnel Pharmaceuticals LLC.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Eli Lilly And Company
  • Johnson & Johnson Services, Inc.
  • Noven Pharmaceuticals, Inc.
  • RespireRx Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Neos Therapeutics, Inc.
  • American Brivision (Holding) Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • GSK plc
  • Purdue Pharma L.P.
  • Cingulate
  • Adlon Therapeutics L.P.
  • Tris Pharma, Inc.
  • Neuraxpharm
  • Supernus Pharmaceuticals, Inc.
  • Aytu Biopharma, Inc.

"*" marked represents similar segmentation in other categories in the respective section.